Besides, recombinant human TRAIL as an anti-cancer therapeutic, which was unsuccessful in clinical trials due to poor bioavailability and short half-life, agonistic TRAIL-receptor antibodies have also shown limited effectiveness. This evidence concerns the gene TNFSF10 and cancer.